Boots Pharmacy Revenue and Competitors
Estimated Revenue & Valuation
- Boots Pharmacy's estimated annual revenue is currently $100.5M per year.
- Boots Pharmacy's estimated revenue per employee is $140,000
Employee Data
- Boots Pharmacy has 718 Employees.
- Boots Pharmacy grew their employee count by 25% last year.
Boots Pharmacy's People
Name | Title | Email/Phone |
---|
Boots Pharmacy Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.7M | 20 | -33% | N/A | N/A |
#2 | $7.5M | 171 | -9% | N/A | N/A |
#3 | $7.5M | 267 | N/A | N/A | N/A |
#4 | $3.5M | 251 | 17% | N/A | N/A |
#5 | $15M | 150 | 8% | N/A | N/A |
#6 | $9.9M | 71 | 22% | N/A | N/A |
#7 | $100.5M | 718 | 25% | N/A | N/A |
#8 | $15M | 214 | -12% | N/A | N/A |
#9 | $75M | 1990 | 6% | N/A | N/A |
#10 | $75M | 812 | 2% | N/A | N/A |
What Is Boots Pharmacy?
Learn about working at Boots Pharmacy. Join LinkedIn today for free. See who you know at Boots Pharmacy, leverage your professional network, and get hired.
keywords:N/AN/A
Total Funding
718
Number of Employees
$100.5M
Revenue (est)
25%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Boots Pharmacy News
2022-04-20 - Boots CEO insists there is still 'a lot of interest' in the group
The boss of UK chemist Boots has pushed back against concerns that a desired £7bn sale is facing subdued demand, instead insisting that...
2022-04-17 - Billionaires: Ambanis Reliance explores bid for Boots pharmacy chain
Mukesh Ambani. Billionaire Mukesh Ambani's Reliance Industries is weighing a possible bid for Walgreens Boots Alliance's international drugstore...
2022-04-06 - Boots owner will reportedly keep stake in chain to ease sale of ...
Walgreens Boots Alliance is reported to have offered to keep a stake of up to 30% in the Boots UK pharmacy chain if and when it is sold,...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $216.4M | 736 | 14% | N/A |
#2 | $159.2M | 784 | 7% | N/A |
#3 | $250.4M | 788 | -1% | N/A |
#4 | $161.4M | 803 | -3% | N/A |
#5 | $75M | 895 | 13% | N/A |